Tin tức & Cập nhật

Adjuvant nivolumab appears to improve survival outcomes in patients with muscle-invasive bladder cancer (MIBC) who have undergone radical surgery, regardless of prior exposure to neoadjuvant chemotherapy, according to additional data from the phase III CheckMate 274 trial.

The combination of the PARP inhibitor talazoparib plus the androgen receptor-pathway inhibitor enzalutamide yields a clinically meaningful increase in the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) being treated in the first-line setting when compared with enzalutamide alone, according to final data from the phase III TALAPRO-2 trial.

Patients with type 2 diabetes (T2D) who use glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) appear to have no increased risk of suicidality when compared with the use of dipeptidyl peptidase-4 inhibitors (DPP-4is) or sodium-glucose cotransporter-2 inhibitors (SGLT-2is), a study has found.